Document |
Document Title |
WO/2020/086732A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
WO/2020/076052A1 |
Provided in the present invention are a novel mixture capable of improving the luminous efficiency, stability and life span of a device, an organic electric device using same, and an electronic apparatus thereof.
|
WO/2020/075790A1 |
The present invention addresses the problem of providing a pharmaceutical product containing, as an active ingredient, a compound having agonistic activity to STING. As a result of extensive investigations, the inventors of the present i...
|
WO/2020/071722A1 |
The present invention provides: a novel mixture capable of improving the luminous efficiency, stability, and lifespan of an element; an organic electronic element using same; and an electronic device thereof.
|
WO/2020/071778A1 |
The present specification provides a heterocyclic compound represented by chemical formula 1, an organic light emitting diode comprising same, a composition for an organic layer of an organic light emitting diode, and a method for manufa...
|
WO/2020/073031A1 |
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to nicotinamide phosphoribosyltransferase (NAM FT) expression. More part...
|
WO/2020/072504A1 |
Disclosed herein is a compound of Formula (I), as described herein, and pharmaceutically acceptable salts thereof. Also disclosed herein are compositions and the use of such compositions in methods of treating a variety of diseases and c...
|
WO/2020/071664A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electr...
|
WO/2020/071720A1 |
The present invention provides: a novel mixture capable of improving the luminous efficiency, stability, and lifespan of an element; an organic electronic element using same; and an electronic device thereof.
|
WO/2020/071721A1 |
The present invention provides: a novel mixture which can improve the luminous efficiency, stability, and service life of an element; an organic electric element using same; and an electronic device thereof.
|
WO/2020/067657A1 |
The present invention relates to a composition for an organic optoelectronic element, an organic optoelectronic element and a display device, the composition comprising: a first compound for an organic optoelectronic element, represented...
|
WO/2020/069179A1 |
The present invention provides a method for chemically modifying a nucleic acid molecule using sulfinate reagents to increase stability in vitro and in vivo. Screening methods for nucleobase modifications that reduce cleavage of a nuclei...
|
WO/2020/065613A1 |
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL ...
|
WO/2020/059985A1 |
A condensed cyclic compound and an organic light emitting diode comprising same are disclosed.
|
WO/2020/060286A1 |
The present invention provides a novel heterocyclic compound and an organic light emitting device using same.
|
WO/2020/060268A1 |
The present invention relates to: a novel sulfonamide derivative with a fused pyrimidine skeleton, represented by chemical formula I; a solvate thereof or pharmaceutically acceptable salts thereof; and a pharmaceutical composition contai...
|
WO/2020/052194A1 |
Disclosed is a fused ring benzothiadiazole non-fullerene acceptor material, a preparation method therefor and a use thereof. The fused ring benzothiadiazole non-fullerene acceptor material comprises a fused ring benzothiadiazole center c...
|
WO/2020/054989A1 |
The present disclosure relates to an organic electroluminescent compound represented by formula 1 and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosu...
|
WO/2020/055164A1 |
Provided in the present invention is the following compound effective in treating and preventing HIF-associated diseases including ischemia and hypoxia by regulating HIF and stabilizing HIF-α. In particular, the compound is effective in...
|
WO/2020/055153A1 |
The present invention relates to a novel serinol-based compound, a cosmetic composition comprising same, and a pharmaceutical composition comprising same. Specifically, the compound according to the present invention promotes differentia...
|
WO/2020/055725A1 |
Disclosed herein are novel methods of treating pain in a patient in need thereof by providing to the patient a selective dopamine D3 receptor antagonist/partial agonist which when used with an opioid analgesic, can mitigate the developme...
|
WO/2020/051207A2 |
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...
|
WO/2020/050546A1 |
The present invention provides a compound represented by formula 1, an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode, and an ...
|
WO/2020/050409A1 |
Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]: wherein ring A, ring B, R1,...
|
WO/2020/045638A1 |
The present invention provides a radiolabeled compound represented by formula (1), which is a radioactive imidazothiadiazole derivative compound having affinity for CA-IX, and salts thereof. In formula (1), n is an integer of 1 to 4 and ...
|
WO/2020/041331A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of alpha-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von H...
|
WO/2020/041405A1 |
The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treat...
|
WO/2020/041169A2 |
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as...
|
WO/2020/041406A1 |
The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treat...
|
WO/2020/040104A1 |
[Problem] To provide a compound having an antiviral action on a virus belonging to the picornavirus genus, specifically, a rhinovirus. [Solution] Provided are a compound represented by general formula (1), a pharmaceutically acceptable s...
|
WO/2020/036812A1 |
The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.
|
WO/2020/036574A1 |
The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.
|
WO/2020/034022A1 |
The present invention relates to the synthesis of a class of fluorophores developed by combining the salicylidene and benzazole classes, and to the compound produced and the technical use thereof in the form of a light emitting diode (WO...
|
WO/2020/030781A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...
|
WO/2020/025543A1 |
The present invention relates to compounds of formula (I) and their use for treating or preventing a bacterial infection or as an antibacterial agent and/or as a β-lactamase inhibitor.
|
WO/2020/021024A1 |
The present invention relates to bicyclic compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or pr...
|
WO/2020/021447A1 |
The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relat...
|
WO/2020/023560A1 |
Isoquinoline compounds of formula (I) variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also de...
|
WO/2020/016264A1 |
The present invention relates to compounds of the formula (1) and mixture comprising these compounds, which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which com...
|
WO/2020/016434A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...
|
WO/2020/015700A1 |
A photothermal agent can be used in both photoacoustic imaging (PAI) and photothermal therapy (PTT) applications. The photothermal agent can include a small molecule, organic compound and/or polymers with absorption in the near-infrared ...
|
WO/2020/010092A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
WO/2020/005877A1 |
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the presen...
|
WO/2019/243530A1 |
The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors having the structure shown in formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds to processes for preparing such compo...
|
WO/2019/243528A1 |
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of ...
|
WO/2019/246085A1 |
Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods.
|
WO/2019/243216A1 |
The present invention relates to a liquid crystalline medium comprising dichroitic dyes made of benzothiadiazoles and related extended heterocyclic derivatives, the use of said medium for optical, electro-optical and electronic purposes,...
|
WO/2019/241292A1 |
Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
|
WO/2019/238616A1 |
The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds a...
|
WO/2019/240676A2 |
Invention relates to a coronary plaque liquefaction/cleaning catheter (A) capable of reaching all coronary arteries (1) in three dimensions and 360 degrees effective for use in atherosclerotic vascular diseases.
|